Mechanism of action of the levonorgestrel-releasing intrauterine system in the treatment of heavy menstrual bleeding

International Journal of Gynecology and Obstetrics

Volumn 123, Issue 2, 2013, Pages 146-149

  Cihangir, Uzunçakmak ^a   Ebru, Akbay ^b   Murat, Ekin ^b   Levent, Yaşar ^b  

^a ISTANBUL TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b BAKIRKOY DR SADI KONUK TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Coagulation; Doppler; Hypercoagulability; Intrauterine device; Levonorgestrel; Levonorgestrel releasing intrauterine system; Thrombocytopenia; Uterine volume

Indexed keywords

FIBRINOGEN; HEMOGLOBIN; LEVONORGESTREL;

ADULT; AMENORRHEA; ARTERY BLOOD FLOW; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEVICE REMOVAL; DOPPLER FLOWMETRY; ENDOMETRIAL THICKNESS; FEMALE; FIBRINOGEN BLOOD LEVEL; FOLLICULAR PHASE; FOLLOW UP; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYSTERECTOMY; IMPLANTATION; INTERNATIONAL NORMALIZED RATIO; LEVONORGESTREL RELEASING INTRAUTERINE SYSTEM; MENORRHAGIA; MENSTRUAL CYCLE; MENSTRUATION; OBSTETRIC ULTRASOUND TRANSDUCER; OLIGOMENORRHEA; OPEN STUDY; ORGAN SIZE; OVARIAN VOLUME; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTHROMBIN TIME; PULSATILE FLOW; RESISTIVE INDEX; SCORING SYSTEM; SPOTTING; THERAPY EFFECT; THROMBOCYTE COUNT; TRANSVAGINAL ECHOGRAPHY; TURKEY (REPUBLIC); UTERINE ARTERY; UTERINE VOLUME; VISUAL BLEEDING SCORE;

COAGULATION; DOPPLER; HYPERCOAGULABILITY; INTRAUTERINE DEVICE; LEVONORGESTREL; LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM; THROMBOCYTOPENIA; UTERINE VOLUME;

ADULT; BLOOD COAGULATION; CONTRACEPTIVE AGENTS, FEMALE; ENDOMETRIUM; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; MENORRHAGIA; MIDDLE AGED; OVARY; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TURKEY; UTERINE ARTERY; UTERUS;

EID: 84885185895     PISSN: 00207292     EISSN: 18793479     Source Type: Journal    
DOI: 10.1016/j.ijgo.2013.05.018     Document Type: Article

References (25)

1. Mansour D, Inki P, Gemzell-Danielsson K. Efficacy of contraceptive methods: A review of the literature. Eur J Contracept Reprod Health Care 2010;15(1):4-16.
2. Willett G. Clinical Review. http://www.fda.gov/downloads/Drugs/ Development ApprovalProcess/DevelopmentResources/UCM245685.pdf. Published March 6, 2009.
3. Marret H, Fauconnier A, Chabbert-Buffet N, Cravello L, Golfier F, Gondry J, et al. Clinical practice guidelines on menorrhagia: management of abnormal uterine bleeding before menopause. Eur J Obstet Gynecol Reprod Biol 2010;152(2):133-7.
4. Lethaby AE, Cooke I, ReesM. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev 2005(4):CD002126.
5. Critchley HO, Wang H, Jones RL, Kelly RW, Drudy TA, Gebbie AE, et al.Morphological and functional features of endometrial decidualization following long-term intrauterine levonorgestrel delivery. Hum Reprod 1998;13(5):1218-24. (Pubitemid 28279173)
6. Janssen CA, Scholten PC, Heintz AP. A simple visual assessment technique to discriminate between menorrhagia and normal menstrual blood loss. Obstet Gynecol 1995;85(6):977-82.
7. Kk T, Ertan K. Continuous oral or intramuscular medroxyprogesterone acetate versus the levonorgestrel releasing intrauterine system in the treatment of perimenopausal menorrhagia: A randomized, prospective, controlled clinical trial in female smokers. Clin Exp Obstet Gynecol 2008;35(1):57-60. (Pubitemid 351345819)
8. L?hteenm?ki P, Haukkamaa M, Puolakka J, Riikonen U, Sainio S, Suvisaari J, et al. Open randomised study of use of levonorgestrel releasing intrauterine system as alternative to hysterectomy. BMJ 1998;316(7138):1122-6. (Pubitemid 28156457)
9. Sivin I, Stern J, Coutinho E, Mattos CE, elMahgoub S,Diaz S, et al. Prolonged intrauterine contraception: A seven-year randomized study of the levonorgestrel 20 mcg/day (LNg 20) and the Copper T380 Ag IUDS. Contraception 1991;44(5):473-80.
10. Wildemeersch D, Schacht E. The effect on menstrual blood loss in women with uterine fibroids of a novel ?frameless? intrauterine levonorgestrel- releasing drug delivery system: A pilot study. Eur J Obstet Gynecol Reprod Biol 2002;102(1):74-9. (Pubitemid 34224081)
11. Backman T, Huhtala S, Blom T, Luoto R, Rauramo I, Koskenvuo M. Length of use and symptoms associated with premature removal of the levonorgestrel intrauterine system: A nation-wide study of 17,360 users. BJOG 2000;107(3):335-9. (Pubitemid 30145374)
12. Cho S, Nam A, Kim H, Chay D, Park K, Cho DJ, et al. Clinical effects of the levonorgestrel-releasing intrauterine device in patients with adenomyosis. Am J Obstet Gynecol 2008;198(4):373.e1-7.
13. J?rvel? I, Tekay A, Jouppila P. The effect of a levonorgestrel-releasing intrauterine system on uterine artery blood flow, hormone concentrations and ovarian cyst formation in fertile women. Hum Reprod 1998;13(12):3379-83. (Pubitemid 29002626)
14. Haberal A, Kayikcioglu F, Gunes M, Kaplan M, Ozdegirmenci O. The effect of the levonorgestrel intrauterine system on uterine artery blood flow 1 year after insertion. Ultrasound Obstet Gynecol 2006;27(3):316-9. (Pubitemid 43735507)
15. Haliloglu B, Celik A, Ilter E, Bozkurt S, Ozekici U. Comparison of uterine artery blood flow with levonorgestrel intrauterine system and copper intrauterine device. Contraception 2011;83(6):578-81.
16. Zalel Y, Shulman A, Lidor A, Achiron R,Mashiach S, Gamzu R. The local progestational effect of the levonorgestrel-releasing intrauterine system: A sonographic andDoppler flow study. Hum Reprod 2002;17(11):2878-80. (Pubitemid 35350905)
17. Jim?nez MF, Vetori D, Fagundes PA, de Freitas FM, Cunha-Filho JS. Subendometrial microvascularization and uterine artery blood flow in IUD-induced side effects (levonorgestrel intrauterine system and copper intrauterine device). Contraception 2008;78(4):324-7.
18. Keung YK, Owen J. Iron deficiency and thrombosis: literature review. Clin Appl Thromb Hemost 2004;10(4):387-91. (Pubitemid 39391300)
19. Mina A, Favaloro EJ, Koutts J. Relationship between short activated partial thromboplastin times, thrombin generation, procoagulant factors and procoagulant phospholipid activity. Blood Coagul Fibrinolysis 2012;23(3):203-7.
20. Bisht D, Gupta SC, Kaushik S, Ganguli G, Mital VP. Fibrinolysis in idiopathic menorrhagia. Indian J Pathol Microbiol 1991;34(3):200-2.
21. Grimes DA, Stuart GS, Levi EE. Screening women for oral contraception: can family history identify inherited thrombophilias? Obstet Gynecol 2012;120(4):889-95.
22. Kadir RA, Chi C. Levonorgestrel intrauterine system: bleeding disorders and anticoagulant therapy. Contraception 2007;75(6 SUPPL.):S123-9. (Pubitemid 46770705)
23. Koh SC, Singh K. The effect of levonorgestrel-releasing intrauterine system use on menstrual blood loss and the hemostatic, fibrinolytic/inhibitor systems in women with menorrhagia. J Thromb Haemost 2007;5(1):133-8. (Pubitemid 44921078)
24. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995;346(8990):1589-93. (Pubitemid 26001840)
25. Gemzell-Danielsson K, Schellschmidt I, Apter D. A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrelreleasing intrauterine contraceptive systems and Mirena. Fertil Steril 2012;97(3) 616-22.e1-3.